Dateline City:
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd., announced today that they have expanded their
collaboration with an agreement to develop, manufacture and
commercialize MK-1293, an insulin glargine candidate for the treatment
of patients with type 1 and type 2 diabetes. Phase III clinical studies
in type 1 and type 2 diabetes will begin soon.
Language:
English
Contact:
Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more